UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

__________________________________________________________________________________

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  September 19, 2014

  

_________________________________________________________________________________

 

AETHLON MEDICAL, INC.

(Exact name of registrant as specified in its charter)

 

Nevada

(State or other jurisdiction of incorporation)

000-21846

(Commission File Number)

13-3632859

(I.R.S. Employer Identification No.)

 

8910 University Center Lane, Suite 660

San Diego, California

(Address of principal executive offices)

  

92122

(Zip Code)

 

 

Registrant’s telephone number, including area code:  (858) 459-7800

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

 
 

 

 

Item 7.01 Regulation FD Disclosure

 

The Registrant disclosed that on Friday, September 19, 2014, it made a presentation at the 2014 Exosomes & SingleCell Analysis Summit in San Diego, California.  A copy of the presentation materials are being furnished as an exhibit to this report and are incorporated by reference into this Item 7.01. Also, the Registrant posted the presentation materials to its website (www.aethlonmedical.com) today, September 23, 2014.

 

Item 9.01 Financial Statements and Exhibits.

   

(d) Exhibits.  The following exhibit is being furnished pursuant to Item 7.01 above.

 

  Exhibit No.   Description
       
  99.1   Aethlon Exosome & SingleCell Analysis Summit Presentation 09-19-14

 

 

 

 

 
 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  AETHLON MEDICAL, INC.
  (Registrant)
     
     
Date: September 23, 2014 By: /s/ James B. Frakes
    James B. Frakes
    Chief Financial Officer

 

 

 

 

 
 

 

 

 

EXHIBIT INDEX

 

Exhibit No.   Description
     
99.1   Presentation Materials